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THE FUTURE OF RENAL TRANSPLANTATION 
Thomas E. Starzl 
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Cadaveric renal transplantation has not yet given 
optimal results. Recent introduction of cyclosporin A 
has, however, already improved the results of primary 
and secondary transplantation. In the light of the re-
sults with cyclosporin A, transplantation in the future 
may be offered more liberally to high risk patients, 
reduce the need for A, Band D matching, render living 
related donor transplantation obsolete and open up trans-
plantation to greater numbers of patients. 
We should take a cold look at the past before specu-
lating about the future (Table I). Kidney transplantation 
as a legitimate clinical venture began in 1962 and 1963 
when the first wave of chronic survivors, mostly recipi-
ents of living related kidneys, began to emerge from a 
handful of transplant clinics. The reason was the com-
bined use of azathioprine and prednisone (double-drug 
therapy). Previously, azathioprine alone had been tried 
but by itself was too ineffective to hold any promise of 
practicality. Double-drug therapy became and has remained 
the standard form of therapy in more than 85% of trans-
plant clinics throughout the world. 
TABLE I. IMMUNOSUPPRESSIVE DRUG REGIMENS USED CLINICALLY 
Year 
Described Place Agents Deficiencies 
1962 Boston 
1963 a~nverI Richmond, 
Boston, Edinburgh 
1966 Denver 
1970 Denver 
1963 Stockholm Thoracic Duct !Jrainage Nuisance; requires 20-30 days 
Total i,:yrnphoid Irradiation 1979 
Cyclosporin A Alone 1978-79 
Cyclosporin A - Steroids 1980 
Palo Alto, 
Minneapolis 
Cambridge 
Denver 
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? dangerous; extensive prepara-
tion; not quickly reversible 
suboptimal 
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In the long run, most of the deviations from 
azathioprine-steroid therapy will probably be footnotes 
in the history of renal transplantation including (Table 
I) the use of ALG as an adjunct, the demonstration that 
cytoxan (cyclophosphamide) could be substituted for 
azathioprine, the use of thoracic duct drainage as a 
means of preoperative lymphoid depletion, and lymphocyte 
depletion by total lymphOid irradiation. Even with all 
of these combinations, the results of cadaveric trans-
plantation, except in isolated centers and small series, 
have been unacceptable. The one year survival of primary 
cadaveric kidneys in the United States has averaged 
about 50%. 
CYCLOSPORIN 
In 1978, Professor noy CaIne of Cambridge, England, 
introduced into clinical use cyclosporin A (cy A), a drug 
that has proven to be the most potent immunosuppressive 
agent yet used. CaIne recommended and has continued to 
believe that this agent should not be systematically used 
with steroids l , a point of view with which we have not 
agreed. In 1979 and subsequently we have shown how the 
optimal use of cyclospor in A is with steroids 2 , a tech-
nique which has been adopted in all American centers 
where cyclosporin A is now being tried. 
Cyclosporin therapY is begun orally on the day of 
operation. In adults, prednisone also is started at 200 
mg on the day of operation and decreased by 40 mg/day so 
that by the sixth day, a maintenance level of 20 mg/day 
is reached. Further reductions are later possible at a 
more gradual rate. The daily starting dose of 17.5 mg 
cyclosporin is reduced if there is evidence of nephrotox-
icity, hepatotoxicity or other side effects. A benign 
course with no rejection is seen in about 40% of primary 
cadaveric recipients. 
In almost as many patients, rejection supervenes. 
However, the rejections are usually easily controlled and 
reversed with boluses of hydr~cortisone or a second 5 day 
burst of prednisone. The lncldence and severity of rejec-
tion is greater after retransplantation than after pri-
mary grafting. The presence of acute tubular necrosis 
postoperatively does not contraindicate cyclosporin 
therapy. 
Between late 1979 and August 1980 our first clinical 
trials with cyclosporin and steroids were begun involving 
57 primary cadaveric recipients and 9 patients undergoing 
cadaveric retransplantation. The cadaveric transplanta-
tions were performed with randomized donor selection and 
with no attempt to exclude immunologically or medically 
high risk candidates. preoperative transfusion was not 
used. Largely because of learning errors, there was a 
13% patient mortality. However the results of kidney 
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survival were still as good or better than any previously 
achieved by us. 
Amongst the 57 patients who received their first 
cadaveric transplants, the actual one year kidney sur-
vival was 00%. One more kidney was lost after the end of 
the first year. Now after a minimum follow-up of almost 
1-1/2 yrs extending out to beyond 2 yrs, 77% of these 
patients remain dialysis free. One of the patients had 
an incidental lymphoma at autopsy which was the only such 
complication in this initial trial. Of the 9 patients 
undergoing cadaveric retransplantation, 6 have achieved 
satisfactory results. 
Armed with this experience, a new series of cadaveric 
transplantations was begun at the University of Pittsburgh. 
The patients were treated in 1981 and follow-ups are 1-1/2 
mos to a year. Thirty-eight patients received primary 
cadaveric grafts, almost all badly matched at the A, B, 
and D loci. About one-fifth of the patients were diabet-
ics, and many were more than 60 yrs old. Thirty-five of 
these 38 kidneys, or more than 92% are still functioning. 
There was one death in the series, from myocardial in-
farction in a patient with good renal function. A second 
kidney was lost immediately because of a blood bank error 
whereby an A kidney was transplanted into an 0 recipient. 
The third kidney was lost in a patient who perforated her 
cecum a few days after transplantation necessitating dis-
continuance of all immunosuppression. 
Similar patients, mostly in a randomized trial, were 
treated with conventional therapy consisting of azathio-
prine and prednisone during the same time. About 45% of 
these kidneys have already been lost, but with no patient 
deaths. The kidney survival divergence has been so ex-
treme that the study was discontinued on grounds that it 
was no longer ethical to persist. 
An additional observation confirming our earlier 
pilot trial in Colorado has been the good survival that 
can be obtained after retransplantation. In most centers 
cadaveric retransplantatiQn has yielded inferior results. 
At the University of Pittsburgh, this had resulted in the 
number of retransplantations being small, only 13 in the 
preceding 2-1/2 yrs. Only 3, or 23%, of these 13 pa-
tients had functioning kidneys by the end of 6 mos. In 
the cyclosporin cases tne degree of success has been al-
most 80% (23 of 28), in spite of the fact that at least 
half of these recipients had widely reacting T-warm anti-
bodies, and in 8 patients the donor lymphocyte cross-
matches with recently stored recipients serum were posi-
tive. The success rate under this circuDstance, which is 
considered to constitute a positive crossmatch and thus 
to preclude transplantation in most centers, is noteworthy. 
However the problem of the positive cytotoxic crossmatch 
remains a vexing one and one which has slightly degraded 
the results in this retransplantation group. 
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FUTURE DIRECTIONS FOR qoM~pmiAkqAqflk 
From this experience which goes back more than 2 yrs 
I think that many tenets of what has been called the 
strategy of transplantation will be revised as cyclosporin-
steroid therapy becomes widely used. 
First I believe that the use of living related donors 
will become obsolete. About a dozen living related donors 
have died throughout the world, and although this mortal-
ity is small, it will no longer be necessary to take this 
risk. Second, the potential importance of matching at 
the A, B, and D loci will be diminished. However, the 
importance of preformed antibody analysis will be as great 
as before. Third, pretransfusion of potential recipients 
will be stopped. One of the penalties for this widespread 
practice is the development of a population of untrans-
plantable patients with broadly reacting cytotoxic anti-
bodies. It seems unlikely that this penalty will be de-
sirable or necessary, and thus pretransplant transfusion 
will be avoided instead of being deliberated advocated. 
Fourth, certain high risk patients including diabetics 
will be easier to treat, potentially realizing the great 
advantage of treating brittle diabetics with the low doses 
of steroids that can be used with cyclosporin. Clearly 
candidacy criteria along other lines will also be liberal-
ized. Fifth, the interface betweeen dialysis and trans-
plantation will be drastically altered. In the United 
States, the numbers of patients undergoing transplantation 
is 5% or perhaps less, of those who are on chronic dialy-
sis programs. One of the reasons has been the understand-
able reluctance of nephrologists who hesitate to refer 
patients doing well on dialysis for cadaver transplanta-
tion, with the bad record which the latter procedure has 
had. Finally as movement occurs toward increasing the 
numbers of cadaveric transplantations, the supply of 
organs, which has not been as major a problem as has often 
been claimed in the lay press, could turn into one of 
crisis proportions. 
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